---
title: "CSPC Pharma Surges Over 8% Amid Mixed Analyst Ratings"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288024206.md"
description: "CSPC Pharma rose 8.05% to HK$7.49 with a turnover of HK$925.21M. Q1 net profit fell 41.8% to RMB 860M."
datetime: "2026-05-29T07:01:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288024206.md)
  - [en](https://longbridge.com/en/news/288024206.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288024206.md)
---

# CSPC Pharma Surges Over 8% Amid Mixed Analyst Ratings

CSPC Pharmaceutical Group (1093.HK) surged over 8% during regular trading hours, currently trading at **HK$7.49**. The stock has seen a significant increase in trading volume, reaching **126.92 million shares**, with a turnover of **HK$925.21 million**.

Recent news highlights include the company's Q1 2026 performance report, which showed a net profit of RMB 860 million, a year-on-year decrease of 41.8%, and revenue of RMB 6.465 billion, down 7.8% year-on-year. Analysts have mixed views, with some maintaining a 'Buy' rating and others expressing concerns over policy risks and declining licensing fee income.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CICC Sticks to Their Buy Rating for CSPC Pharmaceutical Group (CHJTF)](https://longbridge.com/en/news/288013817.md)
- [Jefferies Sticks to Their Sell Rating for CSPC Pharmaceutical Group (CHJTF)](https://longbridge.com/en/news/280592047.md)
- [CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate](https://longbridge.com/en/news/284559073.md)
- [CICC Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF)](https://longbridge.com/en/news/274393834.md)
- [CSPC Pharmaceutical Grants 46.5 Million Restricted Shares to 727 Employees](https://longbridge.com/en/news/273529699.md)